Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities.

However, the PFS, OS, PD-L1 expression level and tumor infiltrating CD8 T cell densities did not reach statistical significance, potentially due to the limited sample size ( n = 25). 140 An evaluation of 153 patients with advanced, EGFR-mutant NSCLC (with only the EGFR Δ19 mutation or EGFR L858R mutation included) showed that patients with high TMB (defined as > 4.85 mutations/Mb) had shorter time-to-treatment discontinuati

also in 111,027 other papers